Death Scare For Pfizer's Pipeline Star Tofacitinib May Be Just A Storm In a Teacup
This article was originally published in The Pink Sheet Daily
Executive Summary
Mortality rate for Pfizer's oral RA drug tofacitinib is similar to what's been seen with established TNF blockers, which have labels warning of potential for death by infection and cancer.
You may also be interested in...
Pfizer Downplays Risk Of Tofacitinib Panel Review As It Pushes Focus On Innovation
Capital allocation and business re-structuring dominated the conversation during Pfizer’s Q1 earnings call –its first full quarter without Lipitor exclusivity, even as the company waits for near-term regulatory decisions on key compounds.
Tofacitinib Data Is In: As Effective As Humira, But Safety Remains A Question
Pfizer Inc. on Sept. 8 released some data from three previously undisclosed pivotal trials for tofacitinib, its high-profile, first-in-class JAK3 inhibitor for rheumatoid arthritis, which it says shows that the drug is equal in efficacy to Abbott Laboratory Inc.’s bestselling TNF inhibitor Humira.
Tofacitinib Data Is In: As Effective As Humira, But Safety Remains A Question
Pfizer Inc. on Sept. 8 released some data from three previously undisclosed pivotal trials for tofacitinib, its high-profile, first-in-class JAK3 inhibitor for rheumatoid arthritis, which it says shows that the drug is equal in efficacy to Abbott Laboratory Inc.’s bestselling TNF inhibitor Humira.